bryostatin-1


Also found in: Encyclopedia.

bryostatin-1

A drug with a unique action against cancer cells, that is being used in trials of treatment of leukaemia and malignant melanoma. Bryostatin is formed by a bacterium Endobugula sertula that parasitizes the boat-fouling marine animal Bugula neritina . The drug also shows promise as a stimulant of the immune system against breast cancer.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
Mentioned in ?
References in periodicals archive ?
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
'Our confirmatory Phase 2 trial is based on clinical data from our previous exploratory Phase 2 trial, which showed significant improvements in Severe Impairment Battery (SIB) scores for patients in the 20-microg Bryostatin-1 dose group not on memantine,' Dr.
Neurotrope has concluded data collection in its confirmatory Phase 2 double blind, placebo controlled clinical trial of Bryostatin-1 in the treatment of moderately severe to severe Alzheimer's disease.
Bryostatin-1 is expected to enter Phase 1b clinical trials in 2020 to study its potential role in enhancing immuno-oncology drugs in the treatment of hematologic (blood) cancers.
M2 EQUITYBITES-February 5, 2019-Neurotrope signs cooperative research and development agreement with the National Cancer Institute for Bryostatin-1 research and clinical development
Global Banking News-February 5, 2019-Neurotrope signs cooperative research and development agreement with the National Cancer Institute for Bryostatin-1 research and clinical development
Neurotrope achieved positive results from a Phase II, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease.
Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism.
Bryostatin-1 has been shown to potently inhibit the growth and self-renewal capacity of human leukemia cells at nanomolar concentrations in vivo and in vitro (26-28).
Dual effects of bryostatin-1 on spatial memory and depression.
For our research, this ecosystem is important because one of the marine animals that resides there, the bryozoa Bugula neritina, contains the FDA-approved natural product bryostatin-1. For example, Figure 3 shows a MALDI-MS analysis of a pentanol extract of sediment from the same ecosystem and illustrates peaks where bryostatin-1 plus [Na.sup.+] would be located (927 m/z).